- Home
- H vs NBIX Comparison
H vs NBIX Comparison
Compare H & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | H | NBIX |
|---|---|---|
| Founded | 1957 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 13.9B |
| IPO Year | 2009 | 1996 |
Fundamental Metrics
Financial Performance| Metric | H | NBIX |
|---|---|---|
| Price | $147.47 | $130.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | $173.53 | ★ $175.27 |
| AVG Volume (30 Days) | 804.3K | ★ 911.3K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | ★ $4,685,000,000.00 | $161,626,000.00 |
| Revenue This Year | $109.88 | $22.85 |
| Revenue Next Year | $6.97 | $9.99 |
| P/E Ratio | ★ N/A | $27.98 |
| Revenue Growth | 5.78 | ★ 977.51 |
| 52 Week Low | $102.43 | $84.23 |
| 52 Week High | $180.53 | $160.18 |
Technical Indicators
Market Signals| Indicator | H | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 48.60 |
| Support Level | $132.28 | $128.03 |
| Resistance Level | $151.03 | $136.74 |
| Average True Range (ATR) | 6.38 | 2.86 |
| MACD | -1.44 | 0.33 |
| Stochastic Oscillator | 27.22 | 48.74 |
Price Performance
Historical ComparisonAbout H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 40 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.